(12) **Translation of European patent specification**

(11) **NO/EP 2683242 B1**

**NORWAY**

(19) NO

(51) Int Cl.

***A61K 31/407 (2006.01)***

***A61P 25/28 (2006.01)***

**Norwegian Industrial Property Office**

| | | |
|---|---|---|
| (45) | Translation Published | 2020.08.17 |
| (80) | Date of The European Patent Office Publication of the Granted Patent | 2020.04.08 |
| (86) | European Application Nr. | 12782326.8 |
| (86) | European Filing Date | 2012.02.28 |
| (87) | The European Application's Publication Date | 2014.01.15 |
| (30) | Priority | 2011.03.04, US, 201113041211 |
| (84) | Designated Contracting States: | AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR |
| | Designated Extension States: | BA ; ME |
| (73) | Proprietor | Annovis Bio, Inc., 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312, USA |
| (72) | Inventor | MACCECCHINI, Maria, 1223 Fox Glove Lane, West Chester, PA 19380, USA |
| (74) | Agent or Attorney | BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge |

(54) Title **EFFECTIVE AMOUNTS OF (3AR)-1,3A,8-TRIMETHYL-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS THEREOF**

(56) References Cited:

US-A1- 2002 094 999
WO-A1-2005/089746
US-A1- 2005 013 869
WO-A2-2010/117727
D. K. Lahiri ET AL: "The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-beta Peptide Levels in Cell Culture and Mice", Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 1, 27 June 2006 (2006-06-27) , pages 386-396, XP055130741, ISSN: 0022-3565, DOI: 10.1124/jpet.106.112102
Maria L Maccecchini ET AL: "Posiphen: Experimental Alzheimer Agent that Lowers Amyloid Precursor Protein Levels in Culture and In Vivo", , 12 July 2009 (2009-07-12), XP055130786, International Conference on Alzheimer's Disease Retrieved from the Internet: URL:http://www.qrpharma.com/pdf/ICAD_Posip hen_06-30-2009.pdf [retrieved on 2014-07-22]
Jack T. Rogers ET AL: "The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen", Journal of Neural

Transmission, vol. 118, no. 3, 8 January 2011 (2011-01-08), pages 493-507, XP055625613, Vienna ISSN: 0300-9564, DOI: 10.1007/s00702-010-0513-5
Maria Maccecchini ET AL: "Targeting Alzheimer's with Novel Therapuetics", , 11 May 2010 (2010-05-11), XP055130807, Neuroscience Network Retrieved from the Internet: URL:http://www.qrpharma.com/pdf/2010-5-11 Alzheimers Research Today Maria Maccecchini slides.pdf [retrieved on 2014-07-22]
HAROLD W HOLLOWAY ET AL: "Posiphen and Analogs: Experimental Alzheimer Agents that Reduce Amyloid-[beta] Peptide by Lowering Amyloid Precursor Protein Levels in Culture and In Vivo", 42ND ANNUAL WINTER CONFERENCE ON BRAIN RESEARCH, 25 January 2009 (2009-01-25), XP055130785, 42nd Annual Winter Conference on Brain Research
MACCECCHINI ET AL.: 'Posiohen lowers amyloid precursor protein and amyloid beta as well as acetylcholinesterase levels in culture, animals and humans' INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE vol. 5, no. 4, 12 July 2009, XP026253808 Retrieved from the Internet: <URL:http://www.qrpharma.com/pdf/ICAD_Posip hen_06-30-2009.pdf> [retrieved on 2012-05-19]
U.S. Department Of Health And Human Services Food And Drug Administration Center For Drug Evaluation And Research (cder): "Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", , 6 July 2005 (2005-07-06), XP055568568, Retrieved from the Internet: URL:https://www.fda.gov/downloads/Drugs/Gu idances/UCM078932.pdf#search='guidekines+for+industry+sfe+starting' [retrieved on 2019-03-13]
Maria L. Maccecchini: "Mechanism of Action of Posiphen : From Model to Human", , 26 January 2011 (2011-01-26), XP055130818, 44nd Annual Winter Conference on Brain Research Retrieved from the Internet: URL:http://www.qrpharma.com/pdf/WCBR Talk Jan 2011.pdf [retrieved on 2014-07-22]
KADIR A ET AL: "Long-term effect of phenserine treatment in Alzheimer patients as assessed by PET and CSF biomarkers", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 5, no. 4, 1 July 2009 (2009-07-01), page P6, XP026897327, ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2009.05.019 [retrieved on 2009-07-01]

# PATENTKRAV

1. Farmasøytisk preparat som omfatter en farmasøytisk akseptabel bærer og en mengde forbindelse (1) eller et salt derav



(1)

for bruk i behandling av demens hos et menneske, hvor fra 3 µg/kg til 1 mg/kg kroppsvekt av forbindelse (1) administreres en gang om dagen,
hvor administrering av nevnte preparat resulterer i et maksimalt plasma-sirkulasjonsnivå av forbindelse (1) lik eller større enn 60 ng/ml i nevnte individ hvorved demens hos nevnte individ blir behandlet.

2. Farmasøytisk preparat for anvendelse ifølge krav 1, hvor nevnte demens er Alzheimers sykdom

3. Farmasøytisk preparat for anvendelse ifølge krav 1, hvor det maksimale plasma-sirkulasjonsnivået er oppnås innen omtrent 6 timer fra administreringstidspunktet.

4. Farmasøytisk preparat for anvendelse ifølge krav 1, hvor plasma-sirkulasjonsnivået av forbindelse (1) er lik eller større enn omtrent 20 ng/ml i minst 12 timer etter nevnte administrering.

5. Farmasøytisk preparat for anvendelse ifølge krav 1, hvor administreringen resulterer i en maksimal plasmakonsentrasjon i nevnte individ av en eller flere verdier valgt fra gruppen bestående av:
(i) minst 20 ng/ml forbindelse (2);



(2)

(ii) minst 20 ng/ml forbindelse (3);



(3)

(iii) minst 2 ng/ml forbindelse (4);



(4)

og en kombinasjon derav.

6. Farmasøytisk preparat for anvendelse ifølge krav 1, hvor administreringen resulterer i en plasmakonsentrasjon med jevnt nivå i nevnte individ av en eller flere verdier valgt fra gruppen bestående av: minst omtrent 100 ng/ml forbindelse (1); minst omtrent 10 ng/ml forbindelse (2); minst omtrent. 10 ng/ml forbindelse (3); minst omtrent 3 ng/ml forbindelse (4); og en kombinasjon derav.